Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2023 Earnings Call Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2023 Earnings Call Transcript November 6, 2023

Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.32 EPS, expectations were $-1.24.

Operator: Good morning and welcome to Axsome Therapeutics Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Later, there will be a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, today’s conference is being recorded. I would now like to turn the conference over to your host Mark Jacobson, Chief Operating Officer at Axsome Therapeutics. Thank you. Please go ahead.

Mark Jacobson: Good morning and thank you all for joining us on today’s conference call. This morning we issued our earnings press release, providing corporate update and details of the company’s financial results for the third quarter of 2023. The release crossed the wire a short time ago is available on our website at axsome.com. During today’s call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our investigational agents, our clinical and nonclinical plans, our plans to present or report additional data, the anticipated conduct and the source of future clinical trials, regulatory plan, future research and development plan, our commercial plans regarding Sunosi, Auvelity, and our other pipeline products, revenue projections and possible intended use of cash and investments.

These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our quarterly and annual report. You are cautioned not to place undue reliance on these forward-looking statements, which are only made as of today’s date and the company disclaims any obligation to update such statements. Joining me on the call today are Dr. Herriot Tabuteau, Chief Executive Officer; Nick Pizzie, Chief Financial Officer; and Lori Englebert, Executive Vice President, Product Strategy.

Herriot will provide an overview of the company and progress made in the third quarter of 2023, as well as key upcoming milestones. Following Herriot, Nick will review our financial results, then Lori will provide a commercial update, we will then open the line for questions. Questions will be taken in the order they are received. And with that I will turn the call over to Herriot.

Herriot Tabuteau: Thank you, Mark. Good morning, everyone, and thank you for joining Axsome Therapeutics third quarter 2023 financial results and business update conference call. In the third quarter, we advanced our differentiated commercial products as well as our broad late-stage neuroscience pipeline. The strong progress in the quarter positions us well to continue delivering potentially life-changing new medicines to patients with serious brain disorders and to their healthcare providers. Total net product revenue in the quarter was $57.8 million, representing significant year-over-year and quarter-over-quarter sequential growth. The quarter’s strong showing reflects contributions from both Auvelity and Sunosi. Auvelity, our first-in-class oral NMDA receptor antagonist and sigma-1 receptor agonist has now been on the market for one year.

Its commercial performance to date reflects its fast onset and lasting efficacy as demonstrated in clinical trials. Later in the call, Nick will provide additional details on our quarterly financials, and Lori will go into more detail on our commercial performance. While we are proud of the positive market reception for Auvelity to-date and the progress we have made with Sunosi, we believe that we have barely scratched the surface of these opportunities. We look forward to continued commercial execution to realize the tremendous potential for these two differentiated medicines. Our commercial success to-date has been enabled by strong clinical profiles for Auvelity and Sunosi and by our efficient, effective, and innovative digital-centric commercialization or DCC approach.

We will continue to deploy this platform with our expanded Auvelity sales force to further drive business performance. In addition, we intend to fully leverage the DCC platform for the potential commercialization of our broad late-stage pipeline. I will provide a brief update on the pipeline progress, including some anticipated upcoming clinical and regulatory milestones. Starting with our two NDA stage products. For AXS-07, for the acute treatment of migraine, we are on track to resubmit the NDA for this product candidate in the first half of 2024. In parallel, we are also working on the NDA submission for AXS-14 for the management of fibromyalgia, which is on track for submission in the first quarter of 2024. Moving on to our Phase III clinical programs, the Phase III SYMPHONY trial of AXS-12 for the treatment of narcolepsy is on track to complete enrollment this year, with announcement of top line results expected in the first quarter of 2024.

The Phase III ADVANCE-2 trial of AXS-05 for the treatment of Alzheimer’s disease agitation is on track for completion in the first half of 2024. In July, we initiated the FOCUS Phase III trial of solriamfetol in ADHD, and we anticipate completion of this trial in the second half of 2024. We previously announced that we intend to develop solriamfetol for the treatment of binge eating disorder and for the treatment of excessive sleepiness associated with shift work disorder. These are two new potential indications with significant patient populations and limited treatment options. We are on track to initiate Phase III trial of solriamfetol in binge eating disorder by the end of this year and in shift work disorder in the first quarter of 2024.

Further details about these clinical programs will be provided at the Solriamfetol Investor Day planned to be held before year’s end. Overall, the third quarter saw us make significant progress with our commercial performance and development pipeline. We expect a closeout this year with continued strong execution setting the stage for productive 2024. I will now turn the call to Nick who will provide details of our financial performance.

Nick Pizzie: Thank you, Herriot, and good morning. Today I will discuss our third quarter results and provide some financial guidance. Total revenue in the third quarter of 2023 was $57.8 million, representing year-over-year growth of 244%. Revenue consisted of net sales of our two commercialized products Auvelity and Sunosi and royalty revenue from Sunosi sales in out-licensed territories. Revenue for the comparable period was $16.8 million comprised only of US Sunosi sales since Auvelity was not launched until October of 2022. Auvelity net sales in the quarter were $37.7 million, representing 36% sequential growth with no net sales in the comparable 2022 period due to the timing of launch. Sunosi net revenue for the quarter was $20.1 million, representing 20% year-over-year growth.

Sunosi net revenue consisted of net sales of $19.4 million and $0.7 million in royalty revenue from sales in the out-licensed territories. Sunosi net revenue for the comparable period was $16.8 million. Cost of revenue was $6.5 million in the quarter compared to $1.9 million in the prior year period. The increase reflects the higher product volumes for both Auvelity and Sunosi in the current year. Research and development expenses were $28.8 million for the third quarter versus $14.9 million for the comparable period in 2022. The increase was primarily related to the FOCUS trial of solriamfetol in ADHD. The advancement of ongoing trials of AXS-05 and AXS-12, CMC costs associated with the NDAs for AXS-07 and AXS-14 post-marketing commitments for Auvelity and Sunosi and higher personnel costs including non-cash stock-based compensation.

Selling, general and administrative expenses were $83.2 million for the third quarter versus $40.9 million for the comparable period in 2022. The increase was primarily related to commercial activities for Auvelity and Sunosi and higher non-cash stock-based compensation expense due to the build-out of both commercial teams. Net loss for the third quarter was $62. 2 million or $1.32 per share versus a net loss of $44.8 million or $1.07 per share for the comparable period in 2022. We ended the quarter with $416.6 million in cash and cash equivalents compared to $200.8 million as of December 31st, 2022. We believe that our current cash balance is sufficient to fund anticipated operations into cash flow positivity based on the current operating plan.

I’ll now turn the call over to Lori who will provide a commercial update.

Lori Englebert: Thank you, Nick, and good morning, everyone. [Technical Difficulty] up to 12 months, all with a favorable tolerability profile. We remain focused on accelerating demand growth [Technical Difficulty] and we expect continued growth in quarter four and beyond. Q3 represents only the third full quarter post-launch for Auvelity. In the quarter, approximately 69,000 prescriptions were written for Auvelity, representing 30% quarter-over-quarter growth. This performance is in contrast to a decline of 1% for the overall antidepressant market during the same period due to market seasonality. In the third quarter, HCPs wrote prescriptions for more than 16,000 new patients, bringing the total number of new patients to start Auvelity since March to approximately 55,000 at the end of Q3.

Prescription growth came from both an increased depth of prescribing with HCP adopters, as well as an increased breadth of new prescribers. In the third quarter, we added approximately 3,200 new first-time prescribers of Auvelity, increasing the cumulative total of prescribers since launch to 13,000. As mentioned during our Q2 earnings call, in response to our early launch success and growing demand, we are expanding the Auvelity field force by about 100 sales representatives to a total of approximately 260. We are on track to complete the hiring of the expanded team by the end of Q4 with completed training and full deployment in the first quarter. The expansion will increase our reach from 26,000 prescribers to approximately 44,000 prescribers.

These 44,000 HCPs write approximately 90% of new-to-brand prescriptions and will substantially increase our potential to reach and help more patients. With regards to payer coverage, we currently have coverage established for 70% of all covered lives. In the commercial channel, which represents the greatest source of volume for Auvelity, coverage is now at 48% of covered lives. In the Medicaid and Medicare channels, approximately 100% of lives are covered. Active discussions with payers continue as coverage expands and evolves. Turning to Sunosi. Total prescriptions for Sunosi in the US grew 16% year-over-year and 5% sequentially. Like Auvelity, Sunosi experienced meaningful demand growth in the third quarter despite the expected overall market decline due to summer seasonality.

The steady growth of Sunosi can be attributed to our focused promotional investments and Sunosi’s differentiated clinical profile. Since Q3 of last year, Sunosi have added 14,000 unique new patients, which represents an increase of [40%] (ph) in cumulative unique patients over the past year. The field team continues to work on driving both depth within the current prescriber base and breadth by adding new prescribers. Since Q3 of last year, we have increased unique new riders of Sunosi by 23%. Payer coverage for Sunosi remains broad, with 95% of commercial lives and 83% of total lives covered. We expect our promotional efforts to drive continued growth for the product in the current indication. In addition, Sunosi has significant growth potential in new target indications, including ADHD, binge eating disorders, and shift work disorders.

Overall both Auvelity and Sunosi deliver strong performance in the quarter. We remain focused on commercial execution to maximize the potential of these clinically differentiated treatments, which address patient populations with high unmet needs. I will now turn the call back to Mark to lead the Q&A discussion.

Mark Jacobson: Thank you, Lori. Operator, may we please have our first question?

See also 20 Most Valuable Financial Companies in the World and Top 20 Most Valuable Esports Companies.

Q&A Session

Operator: Thank you. The floor is now open for questions. [Operator Instructions] Our first question today is coming from Charles Duncan of Cantor Fitzgerald. Please go ahead.

Charles Duncan: Hey, good morning, Herriot and team. Congratulations on a really nice quarter. Thanks for taking our question. I had a couple. One is commercial. One is pipeline. Perhaps for Lori or whoever wants to answer it. Regarding Auvelity, I’m wondering about the drivers of demand in terms of, well, I’m wondering about the drivers of revenue. Are you seeing, are you still seeing more new patient ads versus persistence, or are you starting to see persistence? Because it would seem to me that the product profile would result in patients being on the drug longer than you might expect for an antidepressant?

Lori Englebert: Hey, Charles, I’ll take that question. So it’s a really astute question, so thanks for asking. It is one that we’re still working through. We have just hit our one-year mark, so it’s still a bit hard to comment on the long-term persistence rates for Auvelity. We’re not seeing anything particularly different than what you would expect from the therapeutic area. Feedback, though, from an anecdotal feedback as well as what we’re seeing in refill prescriptions. anecdotal feedback, you know, the product is working per the label. Early on, all we really heard about was the rapid onset of action. But now that we’re just tick past the one-year mark, we are starting to hear about the durability of the effect. So the product is fast and it lasts, which is consistent anecdotal feedback from both HCPs and patients.

And we’re starting to see that through, you know, just the healthy number of refill prescriptions. You know, that’s evidence that clinicians and patients are seeing a response in our continuing treatment.

Charles Duncan: Very good. That’s helpful.

Lori Englebert: Sorry, I was just going to answer the driving of new patients. We’re still very pleased with the number of new patients acquisition that we’re getting on a weekly basis.

Charles Duncan: Okay. That’s a positive. Appreciate it. For Nick, now that you’re through a year, are you contemplating giving guidance next year or is that not yet? Do you feel like you’re not yet there?

Nick Pizzie: Yeah, I think we’re still a bit early on. We’ll continue to ponder that as we get closer towards the end of the year and into 2024. But there’s so many variables at this point that giving guidance is difficult at this point. So, standby, but I hear the question, Charles.

Charles Duncan: Okay. Regarding maybe to Herriot, regarding the pipeline, I had a question about 05. You know, I’m really intrigued with ADVANCE-2 in Alzheimer’s disease agitation. I’m wondering, you sound pretty bullish about being able to read that out in the first half. And I’m wondering if you could characterize the patient sample that you’re enrolling on, obviously, on a blinded basis thus far. How are you confirming Alzheimer’s disease diagnosis or is a symptom presentation across neurodegenerative disease not all that different and so you don’t really need to confirm diagnosis of Alzheimer’s. Thanks.

Herriot Tabuteau: Thanks for the question, Charles. The patient sample that we’re enrolling should match or is matching the patient sample that we enrolled in the ADVANCE-1 trial. And the way that we confirm diagnosis are through validated scales for both Alzheimer’s disease as well as for agitation. Well accepted scales and the same ones that we used in the ADVANCE-1 trial and also that is used in other studies in Alzheimer’s disease.

Charles Duncan: Okay. But you’re not doing imaging, correct? You don’t feel that’s necessary?

Herriot Tabuteau: No. Imaging and —

Charles Duncan: Or biomarkers?

Herriot Tabuteau: And the type of studies is — we are not doing imaging.

Charles Duncan: Okay. Nor blood-based biomarkers?

Herriot Tabuteau: We are not doing imaging or biomarkers for enrollment into the trial, and that’s pretty standard for studies of Alzheimer’s disease that look at cognition or behavioral symptoms.

Charles Duncan: Yeah, thanks. So clinical diagnosis. Okay. Thanks for taking the questions.

Operator: Thank you. The next question is coming from Marc Goodman of Leerink Partners. Please go ahead.

Rudy Li: Hey, morning. This is Rudy on the line for Mark. Thanks for taking my questions. So just a quick follow-up to the ADVANCE-2 questions. So can you talk about your expectations for that coming readout and what data do you think will be adequate to support and identify for this indication? Thanks.

Herriot Tabuteau: So I assume that question has to do with Alzheimer’s disease agitation. And in terms of data from upcoming readouts, we do have the ADVANCE-2 trial. We expect that to complete and readout in the first half of 2024. And that along with the results from our prior studies as well as the ongoing open label safety trial will be will form that the basis for the SMDA filing.

Rudy Li: But do you still need like additional efficacy data from ADVANCE-2 in order to file for that indication?

Herriot Tabuteau: The three studies which are efficacy trials, which will be in the package are the ADVANCE-1 trial, the ACCORD study, as well as the ongoing ADVANCE-2 trial.

Rudy Li: Okay. That’s helpful. Thanks.

Operator: Thank you. The next question is coming from Vikram Purohit of Morgan Stanley. Please go ahead.

Vikram Purohit: Hi. Good morning. Thanks for taking our questions. Two from our side. One on narcolepsy, it seems like there was a little bit of a slip on timing for expected data readout from late this year to one cue of next year. Just wanted to get some context on what might have driven that. And then secondly, for the Auvelity launch, What is your latest sense on the breakup of patients you’re seeing across lines of therapy? Thanks.

Herriot Tabuteau: Great. Thank you. I’ll take the first question and we’ll have Lori take the second question. With regards to narcolepsy and the AXS-12 study, the change in terms of when we expect to have top-line results is driven purely by enrollment. And we’re on track to complete enrollment by the end of the year.

Lori Englebert: Hey, Vikram. So in terms of the type of patients that we’re seeing, right now, about 10% to 12% are first-line therapy, but the majority, and the overwhelming majority is about 60% of the patients that we’re seeing have failed one or two product therapies. So, sum it all up, 70% have failed one or two or brand new to therapy.

Herriot Tabuteau: Yeah. And I would just add that we’re really pleased that this early on in the launch, 40% of patients either are brand new or have failed one treatment.

Vikram Purohit: Understood. Thank you.

Operator: Thank you. The next question is coming from David Amsellem of Piper Sandler. Please go ahead.

David Amsellem: Hey, thanks. Just a couple. So first on the esreboxetine filing and opportunity, how are you thinking about the fit of that commercially within the organization? I mean, my understanding is, it’s a large sort of GP-focused indication. So where does that fit exactly in terms of just where you’re taking the organization? That’s number one. Then number two for reboxetine is your expectation that you’ll be filing on this dataset or are there any other gating items to filing in the narcolepsy setting for that drug. Thanks.

Lori Englebert: Yeah, hi. I’ll take the first one on fibromyalgia. So you’re exactly right. Fibromyalgia is an incredibly underserved market. 5 million patients in the US, only three products approved to treat right now. They’re all generic, widespread. There hasn’t been any promotional dollars in the area for a very long time. Patients, HCPs are all very, very frustrated with this patient type because they don’t have effective products to treat. So, in terms of where we’re taking the market, it’s way too premature for us to speculate on how we will structure our sales force. But what we’re focusing on right now is really making sure that we understand the marketplace, make sure that we have really strong disease state educational efforts to make sure that HCPs and patients are educated well on the disease state, and then we’ll focus our field force on the highest to prescribe, highest likelihood to prescribe HCPs.

Herriot Tabuteau: Great. And then just add to what Lori said. I think one of the things that we’ve always been mindful of in designing our commercial approach is to make sure that we built a commercial infrastructure and platform to enable us to leverage the pipeline. So we’re ready. We’re really happy with the way our DCC or digital central commercialization platform is performing with – to Auvelity as well as the Sunosi and so that experience is allowing us to hone it to make it even better and we will be leveraging that with the fibromyalgia launch. With respect to your question on the reboxetine team and the dataset for the filing, the dataset will consist of the SYMPHONY Phase III trial, which is ongoing, as well as the Concert Phase-II trial. In addition, there is an ongoing open label safety extension trial that is also required for the filing. So those 3 studies will form the basis for the NDA filing.

David Amsellem: Okay, that’s helpful. Thank you.

Operator: Thank you. The next question is coming from Jason Gerberry of Bank of America. Please go ahead.

Jason Gerberry: Oh, hey, guys. Good morning. Thanks for taking my questions. I guess, firstly, just on the patent front, a little surprising, we’re about a year post launch with only a single paragraph for. So curious, any views on your end? Like, what might be going on here perhaps most of the generics are going paragraph three since they can’t get first to file, but on the flip side, maybe this trend might be real and maybe there’s going to be limited IP challenges giving the breadth of your IP. And then my second question is just your thoughts specifically to narcolepsy, maybe how the orexin could competitively have an interplay with 05. You know, it looks like a drug that’s very potent on MWT, but may have a trade-off with insomnia rates as a sleep disorder trade-off. So just curious, your thoughts on the emerging profile of orexin and how that could competitively interplay with 05. Thanks.

Hunter Murdock: Jason, this is Hunter Murdock. Thanks for the question. As a matter of practice, we really can’t comment on ongoing legal proceedings, but, you know, I can tell you we’re very proud of our extensive portfolio on Auvelity and we don’t have any further comment on it.

Herriot Tabuteau: And maybe I’ll touch on your question around the orexin and how they might impact the market. So we like our portfolio, we do have Sunosi, which is approved to treat excessive daytime sleepiness in patients with narcolepsy. And then we have AXS-12 and as you know we’re awaiting the readout of the Phase III trial. And the primary endpoint for that study is cataplexy. So when we think about the market and the need, and I’ll let Lori talk about that, one of the aspects of the disease to be cognizant of is that there are multiple symptoms that these patients experience. So no one treatment will address each symptom. So we like our portfolio which should be able to address more than one of those symptoms, Lori.

Lori Englebert: Yeah, and of those that are on the market and approved right now, you know, patients have to endure really difficult dosing schedules. They trade off efficacy for tolerability or vice versa. So there is still a high unmet need in this [indiscernible] indication for patients.

Operator: Thank you. The next question is coming from Joon Lee of Truist Securities. Please go ahead.

Joon Lee: Hey, thanks for taking our questions. You know binge eating for solriamfetol sounds like it could be either a niche or a huge opportunity. How are you framing the prevalence and commercial opportunity binge eating in the US for solriamfetol? And I will follow up.

Lori Englebert: Hey, Joon. Yeah, we are also very excited about the potential here for binge eating disorder. It is the most common eating disorder. 7 million is the estimated prevalence right now. Only very, very limited treatment options are available for patients. So again high unmet need in a disease that is incredibly prevalent.

Joon Lee: All right. Looking forward to your event on that. On the narcolepsy study, would hitting statistical significance on cataplexy, but not on excessive daytime syndrome keeping us a good outcome or is it your goal to hit statistical significance on both cataplexy and EDS.

Herriot Tabuteau: The primary endpoint of the study is cataplexy, and we’re not going to speculate in terms of what results would be or could be. We’re close. So you’ll know very soon.

Joon Lee: All right. Looking forward. Thank you.

Operator: Thank you. The next question is coming from Ram Selvaraju of H.C. Wainwright. Please go ahead.

Raghuram Selvaraju: Hi. Thanks for taking my questions. The first one is on binge eating disorder. Can you maybe clarify for us what you expect the competitive landscape, if any, to be for your drug candidate, you know, as and when it might secure a label for this indication?

Lori Englebert: Hey, Ram. Yeah, happy to. You know, right now, again, there is, you know, I think one product available for binge eating disorder generic. It is highly prevalent SSRIs, SNRIs being prescribed for the disorder. So we think we have an opportunity to really differentiate ourselves clinically in the marketplace.

Raghuram Selvaraju: Okay, great. And then can you just refresh my memory regarding, you know, your timeline with regard to smoking cessation and ultimately if you could just kind of sketch out for us strategically, assuming a label in that indication, ultimately how you expect promotion activities, sales and marketing activities for that indication to dovetail with what you already have in the field?

Herriot Tabuteau: There is an obvious overlap in terms of therapeutic area for smoking cessation and the rest of our psychiatry and neurology pipeline. So we like the concentration. And I think a lot will depend upon the clinical profile as it evolves from our Phase III trials.

Raghuram Selvaraju: Thank you.

Operator: Thank you. The next question is coming from Joseph Thome of TD Cowen. Please go ahead.

Joseph Thome: Hi, there. Good morning and thank you for taking my question. Maybe the first one on the additional 100 person sales force. Can you go into a little bit more detail on the incremental call points? Are these primary care positions or are they additional specialists that you weren’t seeing earlier and given that the staff is going to be hired, the group is going to be hired by the end of the first quarter, should we expect more of like a Q2 impact from that, or how are you thinking about that? And then second, on the core data presented at CTAD, it looked like dizziness popped up as the largest TEAE, but then impressively that went to zero in a double-blind period. So can you just talk a little bit about dizziness with AXS-05? Does this go away with time? And what’s kind of the grade of that AE? Thank you.

Herriot Tabuteau: Can you start?

Lori Englebert: Hey, Joseph. I’ll address the expansion. So as we mentioned last quarter and refreshed everyone’s memory at this readout, we are expanding our sales force from about 26,000 HCP targets to 44,000 HCP targets. That will take a higher number of PCPs into that number, but what we have remained focused on is the highest likelihood to prescribe HCPs. Of those 44,000 HCPs, they are writing 90% of new branded therapies on a weekly basis. So we feel like we have a great opportunity to tap into optimize the growth of the product.

Herriot Tabuteau: Great. With regards to the question around dizziness in the ACCORD trial, your observations are correct. The dizziness was mild. It was transient. It decreased over time and it did not result in discontinuations.

Joseph Thome: Great. Thank you very much.

Operator: Thank you. The next question is coming from Yatin Suneja of Guggenheim. Please go ahead.

Eddie Hickman: Hi. Good morning, Thanks for taking our questions. This is Eddie on for Yatin. Just one from us. In light of the increasing sales force this quarter, how should we think about the quarter over quarter script increases for Auvelity? And do you expect the increased sales force to really increase cadence then or do you think we’ll have to wait until later in 2024 before we see an inflection there? Thanks.

Lori Englebert: Yeah, hey, Eddie. So as we mentioned before, we should have the field hired and trained and promoting by Q1, but it does take a little time for new sales reps to establish themselves and get out there to produce. So we don’t expect any kind of meaningful uptick until later in the year.

Operator: Thank you. The next question is coming from Graig Suvannavejh of Mizuho Securities. Please go ahead.

Graig Suvannavejh: Good morning. Thanks for taking my questions and congratulations on a good quarter. Just wondering if you could please comment on gross to net in the third quarter for both Auvelity and Sunosi and whether third quarter reported sales for both products reflected any changes in inventory. And I have a follow-up please. Thanks.

Herriot Tabuteau: Sure, Graig. So the growth to net for Auvelity in the quarter was approximately 50%. That was an improvement from the previous quarter, which had a GTN discount that was in the low to mid-50s. Sunosi as well was in that low 50s, very similar to where we saw in the previous quarter. As it relates to inventory, we’ve always shared that. We maintain roughly two weeks of inventory in channels. So there was no inflection as it relates to the sales for inventory for neither Auvelity nor Sunosi.

Graig Suvannavejh: Right, thanks. And then — Sunosi — it’s actually there, you’ve done a nice product, but given peak sales that you’ve put out there of 300 million to 500 million. I’m just wondering if maybe you can comment on kind of how we should expect kind of the time to peak sales and what the dynamic might look like between OSA and narcolepsy. Thanks.

Lori Englebert: Yeah, Graig, I’ll answer and then Nick feel free to chime in if there’s anything else you want to add. So right now the split between OSA and narcolepsy is about 70% OSA, 30% narcolepsy. That’s to be expected. OSA prevalence is about 22 million patients, whereas narcolepsy is 185,000 to 200,000. So we do expect OSA to continue to increase. Right now, of those 22 million OSA patients, only about a million patients are actually drug treated. So, our path to peak sales will come with increased efforts in education and understanding of OSA and treating the disease, which we are very heavily doing and have started doing several quarters ago. So we are anticipating that promotional effort will continue and peak sales will soon follow.

Nick Pizzie: Yeah and the other thing maybe I’ll add is that while we’re continuing to grow very nicely in the US market, ex-US, there’s been a refocus with the Pharmanovia transaction that was announced earlier. And Pharmanovia is really ramping up their sales and marketing strategy. And we would expect to start seeing significant international sales and from our perspective, royalty revenue as it relates to the Pharmanovia strategy.

Graig Suvannavejh: Okay, thank you.

Operator: Thank you. The next question is coming from Myles Minter of William Blair. Please go ahead.

Unidentified Analyst: Hi. Good morning. You’ve got Sarah on for Myles. Congrats on another great quarter. So two quick ones from us. Do you guys have any internal goals about the Auvelity prescribing mix between primary care physicians and specialty referral accounts? And then secondly, is there any read-through or learning from the Rexulti approval in Alzheimer’s disease agitation and how do you see AXS-05 differentiating from that recently approved option? Thanks.

Lori Englebert: Hey, Sarah. I’ll take the first one. So in terms of, you know, goals, we don’t really — we don’t typically look at it that way. As mentioned, we take a look at the prescribers that are most likely to prescribe. Right now, there’s about 80% psych, 20% PCP. That’s to be expected, especially with a novel mechanism of action and a new product coming to market. Consistent with our expansion and as we expand out to broader PCP sets, we do expect that to level out a little bit.

Herriot Tabuteau: Great. And with regards to Rexulti and any learnings from there, we’ve been happy with our clinical development plan with regards to AXS-05 and Alzheimer’s disease agitation. We like the clinical profile thus far from our completed trials, which have been consistent. And we think that it is and will remain differentiated as it relates to Rexulti.

Unidentified Analyst: Great. Thanks for taking the question.

Operator: Thank you. We’re showing time for one final question today. The last question is coming from Matt Kaplan of Ladenburg Thalmann. Please go ahead.

Matt Kaplan: Hey, good morning, guys, and thanks for taking the question, and congrats on the strong quarter. Just wanted to talk a little bit about the ADHD opportunity for Sunosi and what the potential is there and can describe the market maybe more for Lori in terms of the unmet need there.

Lori Englebert: Yeah. Hey, Matt. Yeah, we, again, we are very excited about ADHD for solriamfetol. Prevalence for ADHD across, you know, pediatrics as well as adults and adolescents is about 17 million, so highly prevalent condition. It’s a very large market right now lots of prescriptions on a monthly basis. The way that you can take a look at the market and think about the market now and the way that we’re evaluating is really break it up into stimulants and non-stimulants. Stimulants really have rather large effect sizes, but they do have safety risks that come along with that while your non-stimulants are safer, but they have less effect sizes. So we are excited again for the opportunity for solriamfetol and ADHD.

Matt Kaplan: Thanks again.

Operator: Thank you. At this time, I’d like to turn the call back over to Axsome CEO for any concluding remarks.

Herriot Tabuteau: Well, we thank you all for joining us on today’s call. I am proud of the efforts made by our outstanding team at Axsome. We’re excited by the opportunity ahead of us for both Sunosi and Auvelity as we continue to progress our industry-leading CNS pipeline. As we close out 2023, we are on track to deliver on multiple potentially value-driving milestones on the clinical and regulatory fronts over the next 12 months. Our team is working hard to deliver on our goal of having potentially at least five marketed products by 2025. We look forward to updating you on our progress. Have a great rest of your day.

Operator: Ladies and gentlemen, thank you for your participation. This concludes today’s event. You may disconnect your lines and log off the webcast at this time. And enjoy the rest of your day.